# A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

> **NCT06176352** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 280 (actual)

## Conditions studied

- Choroidal Neovascularization Secondary to Pathologic Myopia

## Interventions

- **DRUG:** Faricimab
- **DRUG:** Ranibizumab
- **PROCEDURE:** Sham Procedure

## Key facts

- **NCT ID:** NCT06176352
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-06
- **Primary completion:** 2025-09-11
- **Final completion:** 2026-05-29
- **Target enrollment:** 280 (ACTUAL)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06176352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06176352, "A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06176352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*